Wheeler Bio, Inc., headquartered in the United States, is a novel force in the contract development and manufacturing organization (CDMO) sector. Founded in 2020, the company operates with the slogan "CMC Made for Biotechs." It focuses on optimizing the transition from discovery to development phases for biopharmaceutical companies, specifically in the development of antibody and antibody-like therapeutics.
Wheeler Bio’s innovative Portable CMC® platform distinguishes it within the Biotechnology, Health and Wellness, and Life Sciences industries. This platform is integral to the company's strategy, designed to mitigate lifecycle challenges while boosting efficiency and promoting strategic partnerships.
In a promising step towards expansion, the company secured a $35.00M Series A investment on March 1, 2025. Key investors include Alloy Ventures, Germin8 Ventures, Echo Investment Capital, Mitsubishi, and Russell Westbrook Enterprises. This infusion of capital reflects investor confidence in Wheeler Bio’s mission and potential to impact the biopharma industry significantly.